Olaparib is an oral PARP inhibitor that was first approved for the treatment of advanced ovarian cancer; however, today, it is applied to patients with recurrent pancreatic cancer carrying BRCA mutations [72]. Here, PARP1 is linked to familial pancreatic carcinoma.